Biocad Wins Approval in Russia for Avastin Biosimilar

The Ministry of Health of the Russian Federation has awarded Biocad marketing authorization for its bevacizumab biosimilar, a knockoff of Roche’s Avastin that slows the growth of new blood vessels.

Included in the federal list of essential drugs, bevacizumab is one of the most expensive therapeutic proteins the Russian government reimburses. The biosimilar will be launched in Russia in the first quarter of 2016.